Regeneron’s COVID-19 antibody cocktail has been added to the UK’s RECOVERY trial, one of the largest of its kind in the world that is testing several potential coronavirus therapies at the ...

Regeneron has said it has begun clinical trials of its antibody cocktail therapy for COVID-19, as pharma companies continue their search for treatments as the pandemic continues to cause havoc ...

Regeneron has leveraged its monoclonal antibody ... yet a windfall from sales of its covid antibody cocktail as well as continuing solid sales of Eylea and Dupixent still gave the firm more ...

What lessons can be learnt from treating Trump? Why is his proclamation of Regeneron's unproven and experimental antibody cocktail so dangerous? What is commission bias? With some updates about ...

Beyond Libtayo, Regeneron's oncology pipeline includes several promising programs that could add significant revenue the coming years. Fianlimab is the company’s LAG3 antibody, which has ...

Regeneron has since re-filed the BCMAxCD3 drug in the U.S., and it's now awaiting a July 10 decision target date. With linvoseltamab's delayed arrival in the U.S., the multiple myeloma bispecific ...

The European Commission (EC) has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic (linvoseltamab) for adults with relapsed and refractory (R/R ...

Regeneron’s Lynozyfic is a bispecific antibody that works by bridging B-cell maturation antigen on MM cells with CD3-expressing T cells to drive T-cell activation and cancer-cell killing. The drug can ...

Scientists identified broadly neutralizing antitoxin antibodies in blood from snake venom-exposed hyperimmune donor for ...

Regeneron’s bispecific antibody linvoseltamab has received conditional approval from the European Commission (EC) for use in relapsed or refractory multiple myeloma. The decision comes just eight ...